In vitro and in vivo characterization of three 68ga-and 111in-labeled peptides for cholecystokinin receptor imaging

Molecular Imaging

Volumn 11, Issue 5, 2012, Pages 401-407

  Roosenburg, Susan ^a   Laverman, Peter ^a   Joosten, Lieke ^a   Eek, Annemarie ^a   Rutjes, Floris P J T ^a   Van Delft, Floris L ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIODISTRIBUTIONS; HUMAN TUMORS; IN-VITRO; IN-VIVO; NUDE MICE; POSITRON EMISSION TOMOGRAPHY (PET); POST INJECTION; SMALL CELL LUNG CANCERS; SPECT/CT; THYROID CARCINOMA; TOMOGRAPHIC; TUMOR UPTAKE;

PEPTIDES; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

TUMORS;

1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; CHOLECYSTOKININ B RECEPTOR; GALLIUM; INDIUM; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMISTRY; EQUIPMENT; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; KIDNEY; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOUSE; NONPARAMETRIC TEST; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; KIDNEY; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; NEOPLASMS, EXPERIMENTAL; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, CHOLECYSTOKININ B; STATISTICS, NONPARAMETRIC; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84873930331     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2012.00001     Document Type: Article

References (13)

1. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCKB/ gastrin receptors in human tumors. Cancer Res 1997;57:1377- 86.
2. Behr TM, Jenner N, Be'hé MP, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029-44.
3. Mather SJ, McKenzie AJ, Sosabowski JK, et al. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007;48:615-22, doi:10.2967/jnumed. 106.037085.
4. Breeman WAP, Froberg AC, de Blois E, et al. Optimised labeling, preclinical and initial aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol 2008;35:839-49, doi:10.1016/ j.nucmedbio.2008.09.006.
5. Roosenburg S, Laverman P, Joosten L, et al. Synthesis and evaluation of 111In-labeled sCCK8 analogues for targeting CCK2- receptor positive tumors. Bioconjug Chem 2010;21:663-70, doi:10.1021/bc900465y.
6. Aloj L, Caraco C, Panico M, et al. In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45:485-94.
7. Be'hé MP, Kluge G, Becker W, et al. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012-5.
8. Nock BA, Maina T, Be'hé MP, et al. CCK-2/gastrin receptortargeted tumor imaging with 99mTc-labeled minigastrin analogs. J Nucl Med 2005;46:1727-36.
9. Laverman P, Behé MP, Oyen WJG, et al. Two technetium-99mlabeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem 2004;15:561-8, doi:10.1021/bc034208w.
10. Brom M, Joosten L, Laverman P, et al. Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/ gastrin receptor-positive tumors. Mol Imaging 2011;10:144-52.
11. Vegt E, van Eerd JE, Eek A, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008; 49:1506-11, doi:10.2967/jnumed.108.053249.
12. Laverman P, Joosten L, Eek A, et al. Comparative biodistribution of twelve 111In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging 2011;38:1410-6, doi:10.1007/s00259- 011-1806-0.
13. Kolenc-Peitl PK, Mansi R, Tamma M, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTAgastrin conjugates for targeting of the gastrin receptor. J Med Chem 2011;54:2602-9, doi:10.1021/jm101279a.